Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.45 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24601620 | 0.94 | ALKBH5 (0.44) | ALKBH5FTOKDM4EMAPTATM | |
| SCHEMBL24601630 | 0.92 | ALKBH5 (0.45) | ALKBH5FTOKDM4EMAPTATM | |
| SCHEMBL24601632 | 0.86 | ALKBH5 (0.44) | ALKBH5FTOKDM4EMAPTATM | |
| SCHEMBL22178604 | 0.85 | KDM4E (0.47) | KDM4EMAPTATML3MBTL1MEN1 | |
| SCHEMBL24601325 | 0.84 | KDM4E (0.48) | ALKBH5FTOKDM4EMAPTATM | |
| SCHEMBL25943016 | 0.83 | ALKBH5 (0.53) | ALKBH5FTOKDM4EMAPTATM | |
| SCHEMBL18706725 | 0.82 | ALKBH5 (0.61) | ALKBH5FTOKDM4EMAPTATM | |
| SCHEMBL24601635 | 0.81 | CYP1A2 (0.36) | KDM4EMAPTTP53CHEK1 | |
| SCHEMBL17995059 | 0.81 | KDM4E (0.48) | ALKBH5FTOKDM4EMAPTATM | |
| SCHEMBL17146748 | 0.79 | KDM4E (0.47) | ALKBH5FTOKDM4EMAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213113-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUNDS, FLUORESCENCE EMITTERS, ORGANIC ELECTROLUMINESCENT DEVICES, AND MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213113-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUNDS, FLUORESCENCE EMITTERS, ORGANIC ELECTROLUMINESCENT DEVICES, AND MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | NCL, NOC2L, NOLC1 | ALKBH5 580/4885FTO 1886/4885KDM4E 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.